Investor Relations

Company Information

MiNK Therapeutics is a clinical-stage biopharmaceutical company committed to developing novel, first-in-class invariant natural killer T (iNKT) cell therapies to transform the lives of patients with cancer.
Press Releases
May 10, 2022
Clinical updates from solid tumor cancers and ARDS with allo-agenT-797 are on track for 2H 2022 GMP manufacturing launch in 1H 2022 with target 10,000 doses/yr BCMA-CAR-iNKT and stromal-CAR-iNKT preclinical results 2H 2022 Ended First Quarter with $34.7M in cash with a projected 2022 cash burn of

Stock Information

Data Provided by Refinitiv. Minimum 15 minutes delayed.

SEC Filings

Form Description Filing date View
SC 13G

A statement of beneficial ownership of common stock by certain persons

View HTML
S-1/A

Amended Registration statement for face-amount certificate companies

View HTML
DRS/A

Amendment to a previously filed DRS

View HTML
DRS/A

Amendment to a previously filed DRS

View HTML

Data provided by Kaleidoscope.